Page last updated: 2024-11-13

guanidinosuccinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

guanidinosuccinic acid: a metabolite in uremia; metabolic product of amino acid metabolism; RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-amidino-L-aspartate(1-) : Conjugate base of N-amidino-L-aspartate arising from deprotonation of the carboxy groups and protonation of the guanidino group; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID25203050
CHEBI ID58005
MeSH IDM0041451

Synonyms (6)

Synonym
guanidinosuccinic acid
n-amidino-l-aspartate(1-)
CHEBI:58005
(2s)-2-{[amino(iminio)methyl]amino}butanedioate
Q27125114
(2s)-2-(diaminomethylideneazaniumyl)butanedioate

Research Excerpts

Overview

Guanidinosuccinic acid (GSA) is a uremic toxin, and its excess accumulation in the CSF under Uremic conditions is thought to produce neural excitotoxicity. It is increased in plasma, urine, cerebrospinal fluid and brain of patients with uremia.

ExcerptReferenceRelevance
"  Guanidinosuccinic acid (GSA) is a uremic toxin, and its excess accumulation in the CSF under uremic conditions is thought to produce neural excitotoxicity. "( Pharmacokinetics of guanidinosuccinic acid in rat blood and cerebrospinal fluid.
Akanuma, S; Hosoya, K; Kasai, Y; Kubo, Y; Tachikawa, M, 2014
)
1.45
"Guanidinosuccinic acid (GSA) is an important probable uremic toxin, increased in plasma, urine, cerebrospinal fluid and brain of patients with uremia and supposed to play a role in the pathogenesis of some neurological symptoms."( GSA: behavioral, histological, electrophysiological and neurochemical effects.
D'Hooge, R; De Deyn, PP; de Vente, J; Marescau, B; Torremans, A; Van Bogaert, PP; Van Dam, D; Van Ginneken, C; Van Meir, F, 2005
)
1.05
"Guanidinosuccinic acid is an aberrant metabolite isolated 40 years ago in the blood and urine of uremic subjects and a suspect in the toxicity associated with renal failure. "( Premature aging in uremia.
Cohen, BD, 2007
)
1.78
"Guanidinosuccinic acid (GSA) is a guanidino compound found in mammalian central nervous system and physiological fluids. "( Epileptiform activity and hippocampal damage produced by intrahippocampal injection of guanidinosuccinic acid in rat.
An, L; D'Hooge, R; De Deyn, PP; Lai, L; Pan, JC; Pei, YQ, 1996
)
1.96

Toxicity

ExcerptReferenceRelevance
" The toxic effects are discussed on the basis of these results."( Comparison of toxic effects of methylguanidine, guanidinosuccinic acid and creatinine in rats with adenine-induced chronic renal failure.
Mo, ZL; Oura, H; Yokozawa, T, 1989
)
0.53

Dosage Studied

ExcerptRelevanceReference
" Ten out of the 23 patients were continuously treated with lactulose at a dosage of 18 g/day for eight weeks."( Short term effect of lactulose therapy in patients with chronic renal failure.
Miura, M; Nomoto, Y; Sakai, H, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
L-alpha-amino acid anionConjugate base of an L-alpha-amino acid arising from deprotonation of the C-1 carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (92)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (32.61)18.7374
1990's36 (39.13)18.2507
2000's19 (20.65)29.6817
2010's7 (7.61)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.45 (24.57)
Research Supply Index4.61 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (3.13%)5.53%
Reviews7 (7.29%)6.00%
Case Studies1 (1.04%)4.05%
Observational0 (0.00%)0.25%
Other85 (88.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]